

## CIDP and CASPR1: A Rare Form of CIDP with Severe Neuropathic Pain

Martin MEM<sup>1</sup>, Mazaro LP<sup>1</sup>, Bandeira IP<sup>1\*</sup>, de Medeiros WLG<sup>1</sup>, Marrone CD<sup>2</sup>, Nascimento O<sup>3</sup> and Gonçalves MVM<sup>4</sup>

<sup>1</sup>Department of Medicine, University of the Region of Joinville (UNIVILLE), Joinville, Santa Catarina, Brazil

<sup>2</sup>Clinica Marrone, Porto Alegre, Rio Grande do Sul, Brazil

<sup>3</sup>Department of Neurology, University Federal Fluminense (UFF), Rio de Janeiro, RJ, Brazil

<sup>4</sup>Department of Neurology, University of the Region of Joinville (UNIVILLE), Joinville, Santa Catarina, Brazil

\*Corresponding author: Isabelle Pastor Bandeira, Department of Medicine, University of the Region of Joinville (UNIVILLE), Joinville, Santa Catarina, Brazil, Tel: +55 41 9 9927-8674; E-mail: isabellepbandeira@gmail.com

Received date: October 7, 2019; Accepted date: October 21, 2019; Published date: October 28, 2019

Copyright: © 2019 Martin MEM, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

### Abstract

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is the most common inflammatory neuropathy. Recently, autoantibodies against the Para nodal proteins are related to a kind of CIDP with a specific clinical and manifestations. The Contactin associated protein-1 (CASPR1) is a cell-adhesion protein tightly associated with Contactin in the Para nodal region and was identified as a possible antigen in inflammatory neuropathies. Patients with CIDP who presents autoantibodies against CASPR1 have a distinct disease course. Therefore, this study proposes that patients with CIDP should be tested to CASPR1.

**Keywords:** CIDP; CASPR1; Autoantibodies; Neuroinflammation

### Commentary


Among inflammatory neuropathies, chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is the most common, with an estimated prevalence of about 0.8 to 8.9 per 100,000 adults, depending on the population studied [1,2]. It mainly affects young adults and the male population; however, it can appear at any age and in both sexes. The disease has a heterogeneous presentation, usually insidious onset and impairs the patients' daily activities, may present a chronic progressive or remitting relapsing course. CIDP seems to affect more the Peripheral Nervous System [1]. The pathophysiology described involves immune-mediated mechanisms and its main feature is symmetrical progressive paresis and impairment of sensory function in the limbs. Clinically, it manifests with paresthesia in the fingers, loss of strength and decreased reflexes in the limbs. This pathophysiological mechanism makes the disease mostly responsive to immunosuppressive therapies [1,3].

CIDP is described as a disorder caused by multifocal demyelination of neurons. The process involves an autoimmune reaction against different neuronal components, especially in the nodal and Para nodal regions. Recently, it had been observed that autoantibodies against the Para nodal proteins are related to a kind of CIDP with a specific clinical and manifestations, which unlike the typical presentation and do not respond as well to immunosuppressive treatment [1,3,4].

CASPR1 is a trans membrane molecule that, associated with neurofascin-155 and contactin-1, forms an important complex in the structure of the Para nodal region and is responsible for mediating the binding between the myelin sheath and the axon [5]. The CASPR1 has its coding gene located on chromosome 17q21.1 and was identified as a possible antigen in inflammatory neuropathies, being responsible for the production of anti-CASPR1 autoantibodies that cause the deposition of IgG immunoglobulin in the Para nodal region. These, in turn, when they bind to immune reactive neurons in the roots of the

dorsal ganglion, trigger a painful clinical presentation. Such pathogenesis is an uncommon but important cause of inflammatory neuropathies and has been little reported until now [4,6].

Patients with CIDP who presents autoantibodies against CASPR1 have a distinct disease course that involves onset at an older age, rapidly progressive course characterized by predominant motor weakness, proximal and distal, than sensitive and severe neuropathic pain [7] (Figure 1).



**Figure 1:** Contactin associated protein 1 (CASPR1) is a cell-adhesion protein located in the paranodal region and it is response to facilitating high-velocity nerve conduction and myelin homeostasis at the central and peripheral nervous system, what explain the severe neuropathic pain and the predominant motor weakness. CIDP: chronic inflammatory demyelinating polyradiculoneuropathy.

In biopsy findings, severe and progressive lesions of the axons are found, as well as few thinly myelinated fibers and absence of onion bulbs, which indicates a different characteristic of the commonly found demyelination. In addition, the myelin sheath is little affected compared to the region Para nodal and Ranvier's nodes, which suffer a breakdown of their normal architectures [8].

Patients who develop antibodies against CASPR1 polyneuropathy present a different clinical course, with an important peripheral involvement [7] and are really important to know this type of CIDP, because the use of intravenous immunoglobulin is ineffective at these patients [3]. We suggest that patients with CIDP phenotype with severe neuropathic pain should be tested to CASPR1, as this clinic does not improve with conventional treatments. Thus, with the correct diagnosis and management of the disease, we save the great discomfort generated in patients, as well as the expenses with medicines that may not be used.

### Conflicts of Interest

The authors declare that there are no conflicts of interest relevant to this work.

### Ethical Approval and Consent to Participate

Not applicable

### References

1. Roggenbuck JJ, Boucraut J, Delmont E, Conrad K, Roggenbuck D (2018) Diagnostic insights into chronic-inflammatory demyelinating polyneuropathies. *Ann Transl Med* 6: 337.
2. McLeod JG, Pollard JD, Macaskill P, Mohamed A, Spring P, et al. (1999) Prevalence of chronic inflammatory demyelinating polyneuropathy in New South Wales, Australia. *Ann Neurol* 46: 910-913.
3. Doppler K, Appeltshauser L, Villmann C, Martin C, Peles E, et al. (2016) Auto-antibodies to contactin-associated protein 1 (Caspr) in two patients with painful inflammatory neuropathy. *Brain* 139: 2617-2630.
4. Calia Leandro C, Oliveira Acary SB, Alberto Alain G (1997) Polirradiculoneuropatia desmielinizante inflamatória crônica: estudo de 18 pacientes. *Arq Neuro-Psiquiatr* 55: 712-721.
5. Rios JC, Melendez-Vasquez CV, Einheber S, Lustig M, Grumet M, et al. (2000) Contactin-associated protein (Caspr) and contactin form a complex that is targeted to the paranodal junctions during myelination. *J Neurosci* 20: 8354-8364.
6. Venken K, Meuleman J, Irobi J, Ceuterick C, Martini R, et al. (2001) Caspr1/Paranodin/Neurexin IV is most likely not a common disease-causing gene for inherited peripheral neuropathies. *Neuroreport* 12: 2609-2614.
7. Querol L, Nogales-Gadea G, Rojas-Garcia R, Martinez-Hernandez E, Diaz-Manera J, et al. (2012) Antibodies to contactin-1 in chronic inflammatory demyelinating polyneuropathy. *Ann Neurol* 73: 370-380.
8. Conant A, Curiel J, Pizzino A, Sabetrasekh P, Murphy J, et al. (2018) Absence of axoglial paranodal junctions in a child with CNTNAP1 mutations, hypomyelination, and arthrogryposis. *J Child Neurol* 33: 642-650.